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Abstract The structural basis for the interaction between 
tenascin-C and the neuronal cell adhesion molecule, contactin/ 
F l l ,  was investigated using plasmon surface resonance technol- 
ogy. The binding site on tenascin-C for contactin/Fll is shown to 
span the two fibronectin type III homology domains 5 and 6. 
Either domain alone is insufficient for binding. Heparin, heparan 
sulfate and dermatan sulfate inhibit this interaction through 
binding to a conserved heparin-binding site on domain 5. In 
contrast, chondroitin sulfates A and C have no such effect. 
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1. Introduction 
Tenascin-C gives its name to a family of extracellular ma- 
trix (ecm) molecules implicated in the regulation of cell-ecm 
interactions. Structurally, they are composed of a series of 
colinear domains whose homologues are found in a wide 
range of proteins with adhesive and signalling functions (see 
Fig. 1). Functionally, tenascin-C can be adhesive or repulsive 
for cells and supports cell migration and neurite outgrowth. 
The natures of the cellular ligands mediating these interac- 
tions are particularly diverse and include integrins, proteogly- 
cans, cell adhesion molecules (CAMs) and a receptor tyrosine 
phosphatase [1 3]. To understand how interactions between 
tenascin and these various receptors might be coordinated, it
is essential to map the receptor binding sites on tenascin, to 
provide a structural basis for functional investigations. 
Here, we examine how the interactions of one of the more 
intriguing receptors, the neuronal CAM contact in/F l l  [4,5], 
can be modulated by glycosaminoglycans. Contactin/F11 is a 
member of the immunoglobulin superfamily (IgSF) and can 
bind to both tenascin-C [6] and tenascin-R [7] (see also [1,8] 
for recent reviews). The binding site on contact in/F l l  for 
tenascin-C lies within the amino-terminal three Ig domains, 
whereas the binding site in tenascin-C is thought to span the 
boundary of the alternatively spliced region of tenascin, as 
contact in/Fl l  binds preferentially to the 190 kDa tenascin 
isoform [6]. 
To examine the properties of this region more closely, we 
prepared bi-domain fusion proteins spanning the alternatively 
spliced region of chicken tenascin (Fig. 1). These constructs 
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represent the tenascin-C isoforms tenl90 (TNfn56) and ten200 
(TNfnD6 and TNfn5D). This was achieved by cDNA frag- 
ments of adjacent ype III domains being synthesized using 
polymerase chain reaction technology from a cDNA clone 
encoding the entire tenascin-C sequence. Only fusion proteins 
containing the fifth type III homology region of tenascin 
bound to heparin-Sepharose and bound biotin-labelled hepar- 
in in solid phase assays. Using this assay system, we also 
localised the binding of heparan sulfate and dermatan sulfate 
to domain five. Molecular modelling of this domain revealed a
conserved heparin-binding motif  which we proposed as the 
putative binding site [9]. 
Here we present evidence that the TNfn56 binds specifically 
to contactin/Fl l ,  an interaction which can be inhibited by 
heparin, heparan sulfate and dermatan sulfate. This raises 
the possibility that cell surface contact in/Fl l  and heparan 
sulfate proteoglycans compete for the same site on tenascin. 
2. Material and methods 
2.1. Purification of prote&s 
Contactin/F11 was purified from chick embryo brains [6]. Briefly, 
embryo day 17 chick brains were extracted with 0.5 M NaC1 in de- 
tergent-free buffer A (20 mM Tris-HC1, 2 mM CaC12, 2 mM MgC12, 
1 mM PMSF, 25 mM e-amino caproic acid, 0.02% NAN3; pH 7.5). 
The extract was cleared by centrifugation (100000xg, 90 min, 4°C), 
diluted with buffer A to 0.2 M NaC1 and passed through a column of 
Sepharose 4B, to remove material binding non-specifically to Sephar- 
ose, followed by columns of T16-Sepharose (anti-tenascin) and 8D9- 
Sepharose (anti-NgCAM) to specifically absorb tenascin-C and 
NgCAM, respectively. The eluate was then applied to a column of 
Concanavalin A-Sepharose. After washing with buffer A containing 
0.2 M NaC1 (buffer B), the Concanavalin A column was eluted with 
buffer B containing 0.1 M methyl-c~-o-mannoside and the eluted peak 
subsequently loaded onto a column of 4D1-Sepharose (anti-contactin/ 
Fll). After a wash with buffer B and then with buffer C (20 mM Tris- 
HC1, 1 mM PMSF, 50 mM NaCl, 0.02% NAN3; pH 7.5), contactin/ 
F11 was eluted with 1 M triethylamine buffer (pH 11.5; 50 mM NaC1, 
0.02% NaN3). The collected fractions were neutralised with 1 M Tris- 
HC1 pH 5.8 and the purity was controlled by SDS PAGE with detec- 
tion by silver staining or immunoblotting with antibodies pecific for 
tenascin-C or tenascin-R or Ng-CAM. 
The expression and native purification of fusion proteins have been 
previously described [9]. Briefly, M15 bacteria were transformed with 
expression plasmids containing the sequence coding for six histidines, 
the factor Xa digestion site (Ile-Glu-Gly-Arg) and the appropriate 
chicken tenascin-C type III domains (Fig. 1). The expression of the 
fusion proteins was induced by adding IPTG to a final concentration 
of 2 mM. After 5 h, the cells were harvested and resuspended in 1/ 
30th detergent-free buffer (25 mM Tris-HCl, 150 mM NaC1, 0.2 mM 
PMSF, 2 mM iodacetamide; pH 8.0) and lysed with a sonifier (Cell 
disrupter, SKAN; setting 4, 6 min, 75%) cooled with ice water. After 
clearing by centrifugation (12 000 x g, 15 min, 4°C; Sorvall SS34), the 
supernatant was diluted with 1.5 vols. loading buffer (67 mM sodium 
phosphate, 300 mM NaC1, 0.02% NAN3; pH 8.0) and loaded onto a 
Ni-NTA column. The column was washed with 67 mM phosphate 
buffer (300 mM NaC1, 0.02% NaNz; pH 6.0) and the fusion protein 
eluted with 100 mM acetate buffer (300 mM NaCI, 0.02% NAN3; 
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pH 3.8). The collected fractions were neutralised with 1 M Tris-HC1 
pH 9. The purity was assayed on 1015% SDS-PAGE and Coomassie 
blue staining. The molecular weights of the three fusion proteins 
TNfn5D, TNfn56 and TNfnD6 are 22638, 22089 and 22 153, respec- 
tively, which are sufficiently close to give a similar signal for each 
fusion protein in surface plasmon resonance analysis. 
The monoelonal antibody 1C10 against he leading polyhistidine 
sequence of the fusion proteins was produced by injecting TNfn56 
into mice with subsequent hybridisation of the spleen cells with mye- 
loma cells. Antibody clones which additionally recognised the fusion 
proteins TNfn5D and TNfnD6 were screened for their affinity to the 
polyhistidines. The factor Xa processed fusion protein missing the 
polyhistidine sequence (TNfn56w/oHis) was used as a negative con- 
trol. One clone selected, designated 1C10, was grown in bulk culture 
roller bottles. The pH of the harvested medium was adjusted to 8.0 
and the medium subsequently loaded onto a TNfnD6 column. After 
washing the column with 67 mM phosphate buffer (300 mM NaC1, 
0.02% NAN3; pH 8.0), the antibody was eluted with 100 mM acetate 
buffer (300 mM NaCI, 0.02% NAN3; pH 3.8) and the collected frac- 
tion was neutralised with 1 M Tris, pH 9.0. The purified antibody 
1C10 was tested for specificity with ELISA on coated TNfn5D, 
TNfn56 and TNfnD6. 
2.2. Plasmon surface resonance analysis 
Plasmon surface resonance analyses were performed with the BIA- 
core biosensor (Pharamacia) using the sensor chip CM5 (Pharmacia). 
All experiments were carried out in HBS (10 mM HEPES, 150 mM 
NaC1, 0.02% NaN3 ; 0.005% surfactant P20) at a flow rate of 5 ktl/min 
at 25°C. Immobilisation of contactin/Fll or 1C10 antibody to the 
chip surface was carried out according to the supplier's instructions. 
Briefly, prior to immobilisation, contactin/Fll was dialysed against 
2.5 mM HEPES (pH 7.4). Immediately before the immobilisation 
procedure, 84 ~tl of contactin (48 ~tg/ml) was mixed with 24 ~tl of 20 
mM acetate buffer (pH 3.5). The chip surface was activated for 10 min 
with a freshly prepared mixture of 0.2 M N-ethyl-N'-(dimethylamino- 
propyl)carbodiimide (EDC) and 0.05 M N-hydroxysuccinimide 
(NHS). The contactin/Fll was allowed to immobilise for 9 min, 
then the remaining activated groups were blocked with 1 M ethanol- 
amine for 7 min. The surface was regenerated during 1 rain with 10 
mM HC1. The coupling of antibody 1C10 was carried out similarly. 
From a stock solution of 1C10 (375 ~tg/ml in 2.5 mM HEPES) 13.5 tll 
were mixed with 86.5 tll 10 mM acetate buffer (pH 5.0) immediately 
before immobilisation. Inhibition studies were performed with chon- 
droitin sulfates A and C, dermatan sulfate, heparan sulfate, heparin 
and low molecular weight heparin (average Mr 3000), all purchased 
from Sigma. 
3. Results 
3.1. Immobilisation of contaetin/Fll and 1 CIO 
To investigate the binding of fusion proteins to contactin/ 
F l l  by means of the BIAcore facility, the contact in/Fl l  
needed to be covalently immobilised to the chip surface. 
The efficiency of coupling can be directly estimated from the 
increase in signal arising after washing away unbound materi- 
al. In the BIAcore system, the signal is measured in response 
units (RU), where 1 RU is equal to about 1 pg/mm 2 protein 
[10,11]. From the increase in RU of 4529 resulting from the 
immobilisation of contact in/Fl l  (135 kDa), its surface con- 
centration can be estimated to be 33.6 fmol/mm z. As a posi- 
tive control, we immobilised the monoclonal antibody 1C10. 
This antibody binds specifically to the polyhistidine sequence, 
which is common to all fusion proteins used in this work (Fig. 
1) [9,12]. Similarly to contact in/Fl l ,  the immobilisation of 
1C10 gives a difference of 5000 RU, equivalent to a surface 
concentration of 33.3 fmol/mm 2 antibody. 
3.2. Binding of fusion protein TNfn56 on contactin/Fl l 
Contact in/F l l  binds preferentially to the TN190 isoform 
where the fibronectin type III domains 5 and 6 are adjacent 
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Fig. 1. Schematic illustration of fusion proteins and the tenascin-C 
isoforms tenl90 and ten200. Tenascin isoforms differ in the number 
of fibronectin type III homology domains, additional domains being 
spliced inbetween TNfn5 and 6. The fusion proteins used in this 
study, TNfn56, TNfn5D and TNfnD6 are representative for this re- 
gion of tenl90 and ten200, respectively. 
(Fig. 1) [6]. This raised the possibility that both domains are 
required for binding and that either domain alone would be 
insufficient. To test this, the fusion proteins TNfn56, TNfn5D 
and TNfnD6 were passed over the contactin/F11 surface at 
different concentrations (Fig. 2). Binding to the immobilised 
ligand can most easily be judged from the off-rate phase, when 
the chip surface is being rinsed with HBS buffer alone. I f  
binding occurs, the protein is retained on the chip surface 
and elutes in a long drawn out curve. In the case of non- 
binding, there is a fast drop in the signal, as exhibited by 
the negative control, BSA on the 1C10 surface. Neither 
TNfn5D nor TNfnD6 appeared to bind, both eluting without 
any retention to immobilised contact in/Fl l .  The binding 
curves for TNfn56 on contact in/Fl l  clearly differ and show 
drawn out dissociation phases. 
In contrast to contact in/F l l ,  all fusion proteins bound to 
the positive control, the immobilised 1C10 monoclonal anti- 
body specific for the polyhistidine sequence (Fig. 2). Applied 
at a concentration of 15 gM, they bound more rapidly than 
TNfn56 to contactin/F11 and were retained more strongly by 
the antibody, indicating both a higher on-rate and slower off- 
rate. The form of the curves closely resembled that of TNfn56 
binding to contact in/Fl l ,  confirming the specificity of this 
interaction. 
3.3. Inhibition of  binding of TNfn56 on contactin/Fll with 
glyeosaminoglycans 
The potential overlap of the contactin/F11 and glycosami- 
noglycan binding sites on TNfn5 raised the possibility that 
these two ligands may interfere in their binding to tenascin. 
To examine this, TNfn56 (44 I.tM) was incubated together 
with LMWH over a range of concentrations and the binding 
to the contactin/F11 surface followed. Relatively low concen- 
trations (4 ~tM) of LMWH are sufficient o effectively inhibit 
the interaction of TNfn56 with the contactin/F11 (Fig. 3). 
Heparin, LMWH,  heparan sulfate and dermatan sulfate 
were previously shown to bind to TNfn5, whereas chondroitin 
sulfates A and C did not [9]. To examine whether the same 
glycosaminoglycans might inhibit the interaction of TNfn56 
and contactin/F11, mixtures of 15 ~tM TNfn56 and 50 p.g/ml 
glycosaminoglycans were injected over the contactin/F11 sur- 
face (50 ktg/ml LMWH corresponds to 16.7 ~tM). The glycos- 
aminoglycans heparin, LMWH,  heparan sulfate and dermatan 
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Fig. 2. Plasmon surface resonance analysis of fusion protein interaction with immobilised contactin/F11 (CN) or monoclonal antibody 1C10. 
Fusion proteins TNfn56, TNfn5D and TNfnD6 were injected over the immobilised contactin/F11 in a series of increasing concentrations. The 
passage of the buffer containing the fusion proteins over the chip surface covers the time interval from 100 to 350 s and can be seen from the 
square profile for the buffer alone (0.0 txM) or from the negative control of BSA in the fourth panel. In the latter, the fusion proteins at a con- 
centration of 15 ~tM were passed over immobilised 1C10 antibody, specific for the polyhistidine s quence. 
sulfate, also inhibited binding of TNfn5 to contactin/Fll, 
with dermatan sulfate having the weakest effect (Fig. 4). In 
contrast, chondroitin sulfates A and C give a signal similar to 
the control without glycosaminoglycan. As expected from the 
previous work, only the L-iduronic acid containing lycosami- 
noglycans are able to inhibit the binding between TNfn56 and 
contactin/F 11. 
4.  D iscuss ion  
We present evidence that the binding site on tenascin-C for 
contactin/F11 spans the TNfn domains 5 and 6. Both domains 
are necessary for binding to contactin/Fll to occur; fusion 
proteins containing either domain in combination with 
TNfnD showed no detectable affinity for immobilised contac- 
tin/F11. The double-domain requirement for binding could be 
independently confirmed through inhibition studies with gly- 
cosaminoglycans. Heparin, heparan sulfate and dermatan sul- 
fate bind specifically to TNfn5, but not to TNfn6 [9]. All three 
glycosaminoglycans al o inhibited the interaction between 
TNfn56 and contactin/F 11in a concentration-dependent ma -
ner. No binding between glycosaminoglycans d contactin/ 
F11 was detected, nor has it been reported by other groups, 
confirming that the heparin-binding site on TNfn5 is targeted 
by this approach. There are no potential oligosaccharide at- 
tachment sites within the domains TNfn5 or 6, making it 
unlikely that carbohydrates on tenascin itself are involved in 
this interaction. 
The requirement of a binding site on tenascin-C spanning 
two domains implies that the binding site in the Ig-like region 
of contactin/F 11similarly spans two Ig-like domains. This can 
be inferred from the similar size and structures of fn domains 
and Ig-like domains [8], which raises the possibility that we 
are observing a side-by-side interaction between the two mo- 
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lecules in a manner closely analogous to that between paired 
immunoglobulin domains. Further evidence in support of this 
model is forthcoming from recent findings on the interaction 
between contactin/F11 and another tenascin family member, 
tenascin-R. The binding site on contactin/F11 for tenascin-R 
had previously been localised to Ig domains 23 [7], suggesting 
that the binding site on contactin/F11 for tenascin-C and te- 
nascin-R is either overlapping or the same. Most recently, 
evidence for a contactin/F11 binding site in chick TN-Rfn23 
was presented [13]. Of particular interest was the requirement 
of both tenascin-R domains 2 and 3 for binding, either do- 
main alone being insufficient. This opens the possibility that 
TN-Cfn56 and TN-Rfn23 may compete for the same site on 
contactin/Fl l .  However, no evidence has yet been presented 
that TN-Rfn23 carries a heparin binding site, nor is such a 
site evident by inspection. This implies that only the interac- 
tion between tenascin-C and contactin/F11 would be inhibited 
by heparan sulfate proteoglycans. Tenascin-C binds two dif- 
ferent heparan sulfate proteoglycans, yndecan [14] and glypi- 
can [15], although whether the heparin binding site on TNfn5 
or a second site in the C-terminal of tenascin [16,17] is respon- 
sible for the binding of the heparan sulfate proteoglycans is as 
yet unknown. 
Glypican, like contactin/F11, is anchored to the membrane 
via glycosylphosphatidylinositol (GPI), leaving both proteins 
freely mobile within the plane of the membrane. Because they 
have no transmembrane domains, signal transduction by such 
GPI-anchored receptors is likely to be particularly dependent 
on receptor (re)organisation i duced by binding to extracel- 
lular ligands. Indeed, we have recently shown that antibody- 
induced aggregation of contact in/Fl l  in neuronal cells leads 
to a co-aggregation of the non-receptor protein tyrosine ki- 
nase Fyn and its transient activation [18]. The competition 
between heparan sulfate and contactin/F11 for the same site 
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Fig. 3. Binding of TNfn56 to contactin/Fll in the presence of in- 
creasing concentrations of low molecular weight heparin (LMWH). 
TNfn56 (44 IxM) was preincubated with LMWH at the concentra- 
tions indicated and the interaction with contactin/Fll immobilised 
to the chip surface measured by plasmon resonance. 
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Fig. 4. Influence of different glycosaminoglycans on binding of 
TNfn56 to contactin/Fll. TNfn56 (15 ~tM) was preincubated with 
50 ~tg/ml of either chondroitin sulfates A or C (CS A or C) or der- 
matan sulfate (DS) or heparan sulfate (HS) or low molecular weight 
heparin (LMWH) or heparin and the mixture injected over contac- 
tin/Fll immobilised to the chip surface. As a positive control, 
TNfn56 was injected alone. 
on tenascin-C, points towards a further level of complexity in 
the organisation of cellular signalling complexes by tenascin 
and provides a fertile field for further investigations. 
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